FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2169199114> ?p ?o ?g. }

• W2169199114 endingPage "423" @default.
• W2169199114 startingPage "423" @default.
• W2169199114 abstract "s 423 Lamotrigine-related rash: an audit I. Wang*, G. Mawer? J University of Bradford, Bradford, UK; t David Lewis Centre for Epilepsy Cheshire, UK; $ institute of Neurology National Hospital for Neurology and Neurosurgery, London, UK Purpose: 1. To estimate the incidence of serious and non-serious rashes associated with lamotrigine (LTG) treatment. 2. To identify risk factors for LTG-related rash. 3. To assess the effectiveness of the recommendation by the manufacturers to reduce starting dose. Methods: Case records were surveyed in five tertiary referral epilepsy centres in the UK. The causality of the rash was assessed using the WHO method. Risk factors for LTG-related rash were identified by logistic regression. The incidences of rash before and after reduction in starting dose were compared by Chi-square. Results and discussion: 1050 patients were included. The incidences of serious and non-serious rash were 1.1% (95% CI = 0.5% to 1.8%) and 7% (95% CI = 5.5% to 8.6%). This study confirms previous reports that concurrent sodium valproate and a high starting daily dose increase the risk of LTG-related rash, while concurrent enzyme inducers reduce it. Furthermore, female patients were twice as likely to develop rash than males. Some clinicians ignored the recommendation to start LTG at a lower dose, consequently, there was no reduction in the incidence of LTG-related rash since the manufacturer recommended reducing the starting dose of LTG. The post-marketing surveillance of gabapentin, lamotrigine and vigabatrin in patients with chronic epilepsy I. Wang*, G. Mawet-+ & J. Sander* *School of Pharmacy, University of Bradford, Bradford, UK; + David Lewis School of Epilepsy Cheshire, UK; $ Institute of Neurology, National Hospital for Neurology and Neurosurgery, London, UK Purpose: A post-marketing surveillance study of gabapentin (GBP), lamotrigine (LTG) and vigabatrin (VGB) investigated adverse drug reactions (ADRs) and mortality. Methods: Case records were surveyed in five tertiary referral epilepsy centres in the UK. Adverse events were recorded and compared within and between the drugs. All deaths were followed and standardized mortality ratios (SMRs) calculated. Serious ADRs were assessed individually. Results and discussion: 1375 patients were included in the statistical analyses. ADRs to GBP were generally mild but one case of leucopenia was identified. Skin rash was the major ADR to LTG but rare cases of hepatic failure, acute exacerbation of ulcerative colitis, disseminated intravascular coagulation and renal failure were also identified. Psychiatric/behavioural disturbance was the major ADR to VGB but one case of visual field constriction was identified. No death could be directly attributed to the use of the new drugs. The SMRs were slightly higher than that reported in the literature. This probably reflects the severity of epilepsy in the study population. Beneficial effect of levetiracetam (UCB L059) on juvenile myoclonic epilepsy resistant to valproate and lamotrigine Kate Smith, Tim Betts & Cathy Fox Birmingham University Seizure Clinic, Queen Elizabeth Psychiatric Hospital, Birmingham B 15 2QZ, UK Levetiracetam (UCB L059) is a new antiepileptic drug (an enantiomer of piracetam) currently undergoing evaluation and already of proven efficacy in patients with partial onset epilepsy. We have examined the effect of this drug on a sub-group of nine patients with juvenile myoclonic epilepsy resistant to conventional therapy with sodium valproate and lamotrigine. Seven of these patients have become totally seizure-free-the other two almost completely so (still in dose escalation). This intriguing result is worthy of further study particularly because Levetiracetam has an acceptable side effect profile." @default.
• W2169199114 created "2016-06-24" @default.
• W2169199114 creator A5064819258 @default.
• W2169199114 creator A5067817690 @default.
• W2169199114 creator A5073823710 @default.
• W2169199114 date "1998-10-01" @default.
• W2169199114 modified "2023-10-18" @default.
• W2169199114 title "Lamotrigine-related rash: an audit" @default.
• W2169199114 doi "https://doi.org/10.1016/s1059-1311(05)80021-4" @default.
• W2169199114 hasPublicationYear "1998" @default.
• W2169199114 type Work @default.
• W2169199114 sameAs 2169199114 @default.
• W2169199114 citedByCount "0" @default.
• W2169199114 crossrefType "journal-article" @default.
• W2169199114 hasAuthorship W2169199114A5064819258 @default.
• W2169199114 hasAuthorship W2169199114A5067817690 @default.
• W2169199114 hasAuthorship W2169199114A5073823710 @default.
• W2169199114 hasBestOaLocation W21691991141 @default.
• W2169199114 hasConcept C118552586 @default.
• W2169199114 hasConcept C121955636 @default.
• W2169199114 hasConcept C144133560 @default.
• W2169199114 hasConcept C16005928 @default.
• W2169199114 hasConcept C199521495 @default.
• W2169199114 hasConcept C2778186239 @default.
• W2169199114 hasConcept C2778570526 @default.
• W2169199114 hasConcept C2778802184 @default.
• W2169199114 hasConcept C71924100 @default.
• W2169199114 hasConceptScore W2169199114C118552586 @default.
• W2169199114 hasConceptScore W2169199114C121955636 @default.
• W2169199114 hasConceptScore W2169199114C144133560 @default.
• W2169199114 hasConceptScore W2169199114C16005928 @default.
• W2169199114 hasConceptScore W2169199114C199521495 @default.
• W2169199114 hasConceptScore W2169199114C2778186239 @default.
• W2169199114 hasConceptScore W2169199114C2778570526 @default.
• W2169199114 hasConceptScore W2169199114C2778802184 @default.
• W2169199114 hasConceptScore W2169199114C71924100 @default.
• W2169199114 hasIssue "5" @default.
• W2169199114 hasLocation W21691991141 @default.
• W2169199114 hasOpenAccess W2169199114 @default.
• W2169199114 hasPrimaryLocation W21691991141 @default.
• W2169199114 hasRelatedWork W1976470591 @default.
• W2169199114 hasRelatedWork W2005114999 @default.
• W2169199114 hasRelatedWork W2067488182 @default.
• W2169199114 hasRelatedWork W2080894976 @default.
• W2169199114 hasRelatedWork W2094313796 @default.
• W2169199114 hasRelatedWork W2142035699 @default.
• W2169199114 hasRelatedWork W2147702016 @default.
• W2169199114 hasRelatedWork W2259928828 @default.
• W2169199114 hasRelatedWork W2514241918 @default.
• W2169199114 hasRelatedWork W2945807772 @default.
• W2169199114 hasVolume "7" @default.
• W2169199114 isParatext "false" @default.
• W2169199114 isRetracted "false" @default.
• W2169199114 magId "2169199114" @default.
• W2169199114 workType "article" @default.